Superworth

Ginkgo Bioworks PE ratio DNA

Share price divided by earnings per share over the last twelve months, since 2020.

Today, Oct 23, 2026
n/m
not a meaningful number
Earnings per share, 12 months
−$5.65
to Dec 31, 2025
Share price
$9.99
Oct 23, 2026
Peer median
14.1×

Ginkgo Bioworks' PE ratio is not a meaningful number today: diluted EPS for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It has had no meaningful PE for most of its history, so the chart below shows the earnings per share a PE divides the price by.

Earnings per share over time

A PE divides the share price by these earnings. While they were a loss or a sliver, the PE meant nothing, so this chart shows the earnings themselves.

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$5.65n/a
FY2024−$10.63n/a
FY2023−$18.49n/a
FY2022−$51.20n/a
FY2021−$49.20n/a
FY2020n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q4 FY25−$1.42n/a−$5.65
Q3 FY25−$1.45n/a−$6.23
Q2 FY25−$1.10n/a−$5.86
Q1 FY25−$1.68n/a−$8.99
Q4 FY24−$2.00n/a−$10.63
Q3 FY24−$1.08n/a−$12.91
Q2 FY24−$4.23n/a−$18.04
Q1 FY24−$3.32n/a−$17.41
Q4 FY23−$4.28n/a−$18.49
Q3 FY23−$6.21n/a−$17.81
Q2 FY23−$3.60n/a−$28.00
Q1 FY23−$4.40n/a−$40.80

Against its peers

Companies in Biotechnology nearest Ginkgo Bioworks' size, closest first, today.

CompanyPE ratio
DNAGinkgo Bioworksn/m
MGTXMeiraGTx13.0×
VCELVericel92.5×
PLXProtalix BioTherapeutics11.1×
ADMAAdma Biologics15.3×
Peer median14.1×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Ginkgo Bioworks

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.